# DESCRIPTION

## FIELD OF INVENTION

- introduce oligonucleotides and in vitro cell based assays

## BACKGROUND

- motivate antisense oligonucleotides
- limitations of in vitro toxicity assays
- need for predictive assays

## SUMMARY OF THE INVENTION

- introduce in vitro toxicity assays
- use primary mammalian hepatocytes
- identify molecular markers of toxicity
- correlate with in vivo toxicity profile
- provide effective in vitro assay
- select oligonucleotide compounds
- administer oligonucleotide to hepatocytes
- measure biomarkers of toxicity
- select oligonucleotides without adverse toxicity
- determine likely in vivo toxicity
- use biomarkers for toxicity
- provide method for selecting oligonucleotides

## DETAILED DESCRIPTION OF THE INVENTION

### Prediction of In Vivo Toxicity

- predict in vivo toxicity of oligonucleotide
- determine likely in vivo toxicity profile

### Primary Mammalian Hepatocyte Cells

- introduce primary mammalian hepatocyte cells
- describe liver perfusion methods
- select primary mammalian hepatocyte cells
- identify predictive biomarkers
- describe co-culture of primary mammalian hepatocytes and non-parenchymal cells

### Administering the Oligonucleotide—Gymnotic Delivery (Gymnosis)

- administer oligonucleotide to primary hepatocyte cells
- describe gymnotic delivery process
- identify culturing period
- describe cell culture conditions
- measure biological effect of oligonucleotide

### Control Data/Reference Values

- determine control data/reference values
- compare biomarker levels to control data
- identify alteration of biomarker levels

### (Determination of) Hepatotoxicity

- define hepatotoxicity
- introduce serum transaminases as liver toxicity biomarkers
- describe in vivo oligonucleotide hepatotoxicity determination
- outline screening library of variants to identify child oligonucleotides
- detail steps of selecting oligonucleotides with reduced toxicity
- describe optional in vivo administration of selected oligonucleotides
- introduce stereodefined oligonucleotides with reduced in vivo toxicity
- describe method of reducing toxicity of antisense oligonucleotide sequence
- outline method of reducing toxicity of phosphorothioate oligonucleotide sequence
- describe subsequent manufacturing step of stereodefined phosphorothioate oligonucleotides

### Parent Oligonucleotide

- define parent oligonucleotide

### Library of Variants

- introduce library of variants of parent oligonucleotide
- describe creation of library of stereodefined oligonucleotide variants
- outline characteristics of child oligonucleotides
- describe stereodefined phosphorothioate linkages in child oligonucleotides
- introduce percentage of stereodefined phosphorothioate linkages
- describe creation of child oligonucleotides by inserting stereodefined linkages
- outline characteristics of remaining internucleoside linkages
- describe retaining pattern of modified and unmodified nucleosides

### Stereodefined Oligonucleotide Embodiments:

- outline method of reducing toxicity
- describe variations of method
- specify characteristics of oligonucleotide variants
- detail potency and toxicity of stereodefined compounds

### Primary Hepatocytes Assay Example:

- describe cell culture conditions
- outline protocol for hepatotoxicity assay

## Definitions

### Oligonucleotide

- define oligonucleotide
- describe structure and synthesis
- specify length and composition
- outline applications

### Antisense Oligonucleotides (ASOs)

- define antisense oligonucleotides
- describe types and characteristics

### Modified Internucleoside Linkages

- introduce modified linkages
- describe phosphorothioate linkages
- outline other linkage options

### Modulation of Expression

- define modulation of expression
- describe types of modulation

### Modified Oligonucleotides

- introduce modified oligonucleotides
- motivate phosphorothioate internucleoside linkages
- describe high affinity modified nucleosides
- summarize sugar modifications
- introduce 2′ modified nucleosides
- describe locked nucleic acid nucleosides
- provide general formula for LNA oligomers
- detail substituents for LNA oligomers
- define modified oligonucleotides
- specify biradical structures
- describe LNA unit structures
- specify nucleobase structures
- define modified oligonucleotides
- describe biradical R4* and R2*
- specify biradical C(RaRb)—N(Rc)—O—
- specify biradical C(RaRb)—O—C(RcRd)—O—
- specify biradical —CH(Z)—O—
- describe bicyclic nucleotides
- specify biradical -Cq3q4-NOR—
- describe R1*, R2, R3, R5, R5*
- specify biradical C(RaRb)—O—
- specify biradical -Q-
- describe LNA structure
- define modified oligonucleotides
- introduce LNA nucleosides
- describe gapmer structure
- detail gapmer designs
- specify gap region composition
- describe wing regions composition
- provide examples of gapmers
- discuss substituents at 2' position
- describe shortmer gapmers
- introduce stereodefined gapmers
- describe phosphorothioate linkages
- define modified oligonucleotides
- describe gapmer oligonucleotide structure
- specify internucleoside linkages in gapmer
- introduce stereodefined phosphorothioate linkages
- define LNA gapmer
- describe mixed wing gapmer
- define gapbreaker oligonucleotide
- specify gapbreaker oligonucleotide structure

### RNase H Activity and Recruitment

- define RNase H activity

### Efficacy

- motivate efficacy testing
- describe efficacy metrics
- specify efficacy thresholds

### Conjugate Moieties

- list conjugate moiety types

### Stereodefined Oligonucleotides

- define stereodefined oligonucleotides

## Immunotoxicity Biomarker Assay:

- describe method for predicting immunotoxicity of oligonucleotides

## EXAMPLES

### Example 1

- describe mouse liver perfusion and hepatocyte and nonparenchymal cell isolation
- describe hepatocyte culturing and oligonucleotide treatment
- describe co-culturing of mouse NPCs and hepatocytes
- describe use of alternative cell types
- describe RNA isolation and qPCR
- describe LDH, albumin, GSH, and ATP assays
- describe apoptosis assay
- describe cytokine measurement
- describe miRNA analysis

### Example 2

- describe evaluation and validation of in vitro hepatotoxicity assays

### Example 3

- describe effect of in vivo safe and toxic oligonucleotides on hepatocyte function and cell viability

### Example 4

- describe ASO-mediated effect on apoptosis

### Example 5

- describe effect of hepatotoxic ASOs on hepatocyte-NPC co-cultures

### Example 6

- describe changes in secreted cytokines and miR-122 upon ASO treatment

### Example 7

- describe miR122-release in supernatants of hepatocyte-NPC co-cultures

### Example 8

- describe testing of 34 ASOs in in vitro hepatotoxicity assay

### Example 9

- describe establishment of protocol for human primary hepatocytes

